AURN001
Alcon Secures Control of Aurion Biotech in Strategic Takeover
Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute
Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema
Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development
Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema
AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results